RESUMEN
A FGLamide allatostatin neuropeptide mimic (H17) is a potential insect growth regulator which inhibits the production of juvenile hormone by the corpora allata. To find more evidence to reveal the structure-activity relationships of the Phe(3) residue in the C-terminal conserved pentapeptide and search for novel analogs with high activity, a series of Phe(3) residue-modified analogs were designed and synthesized using H17 as the lead compound. Bioassay using juvenile hormone (JH) production by corpora allata of the cockroach Diploptera punctata indicated that analogs 4, 11, and 13 showed strong ability to inhibit JH production in vitro, with IC50 of 38.5, 22.5, and 26 nM, respectively. As well, the activity of analog 2 (IC50 : 89.5 nM) proved roughly equivalent to that of H17. Based on the primary structure-activity relationships of Phe(3) residue, we suggest that for analogs containing six-membered aromatic rings, removing the methylene group of Phe(3) or an o-halogen or p-halogen-substituted benzene ring could increase the ability to inhibit biosynthesis of JH. This study will be useful for the design of new allatostatin analogs for insect management. Copyright © 2016 European Peptide Society and John Wiley & Sons, Ltd.
Asunto(s)
Corpora Allata/efectos de los fármacos , Antagonistas de Hormonas/síntesis química , Proteínas de Insectos/antagonistas & inhibidores , Hormonas Juveniles/antagonistas & inhibidores , Neuropéptidos/síntesis química , Peptidomiméticos/síntesis química , Secuencia de Aminoácidos , Animales , Cucarachas/efectos de los fármacos , Cucarachas/genética , Cucarachas/metabolismo , Corpora Allata/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Regulación de la Expresión Génica , Antagonistas de Hormonas/farmacología , Proteínas de Insectos/biosíntesis , Proteínas de Insectos/genética , Hormonas Juveniles/biosíntesis , Hormonas Juveniles/genética , Masculino , Neuropéptidos/farmacología , Peptidomiméticos/farmacología , Fenilalanina/química , Fenilalanina/metabolismo , Relación Estructura-ActividadRESUMEN
Ligands of 18-kDa translocator protein (TSPO) are known for their ability to potently and dose-dependently stimulate steroid biosynthesis in steroidogenic cells. In this study, we investigated a number of 2-phenyl-imidazo[1,2-a]pyridine acetamide derivatives, analogs of alpidem, for their ability to bind TSPO and to affect steroidogenesis in a mouse Leydig tumor cell line. We observed that not only some compounds behaved as agonists, stimulating steroidogenesis (e.g., 3 and 4) with EC50 values (15.9 and 6.99µM) close to that determined for FGIN-1-27 used as positive control (7.24µM), but two compounds, namely 5 and 6, which on the other hand are the most lipophilic ones in the investigated series, behaved as antagonists, by significantly inhibiting steroid production at concentrations at least twenty times lower than the cytotoxic ones. To our surprise, the newly synthesized compound 3, which is a strict analog of alpidem bearing at the para position of the 2-phenyl group a methoxy group instead of chlorine, achieved a ten-fold stimulation of the steroid production (for comparison FGIN-1-27 achieved 1.6-fold stimulation). Within the limits of the examined property space, some unprecedented SARs were unveiled, which can help in understanding the key molecular factors underlying the transition from agonism to antagonism in the steroidogenesis process. Besides the substitution pattern and the physicochemical features (mainly hydrogen bonding potential) of the substituents at the positions C(6) and C(8) of the imidazo[1,2-a]pyridine nucleus, and at the para position of the 2-phenyl group, the structure-activity relationship analysis suggested lipophilicity, whose increase seems to be generally related to steroidogenesis inhibition, and steric hindrance, which appeared as a stimulation-limiting factor, as two main properties to control in the design or optimization of novel imidazo[1,2-a]pyridine-based TSPO ligands endowed with potential in modulating the steroidogenesis process.
Asunto(s)
Antineoplásicos Hormonales/farmacología , Antagonistas de Hormonas/farmacología , Imidazoles/farmacología , Tumor de Células de Leydig/tratamiento farmacológico , Neoplasias Hormono-Dependientes/tratamiento farmacológico , Piridinas/farmacología , Receptores de GABA/efectos de los fármacos , Inhibidores de la Síntesis de Esteroides/farmacología , Neoplasias Testiculares/tratamiento farmacológico , Animales , Antineoplásicos Hormonales/síntesis química , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Antagonistas de Hormonas/síntesis química , Enlace de Hidrógeno , Imidazoles/síntesis química , Tumor de Células de Leydig/metabolismo , Tumor de Células de Leydig/patología , Ligandos , Masculino , Ratones , Estructura Molecular , Neoplasias Hormono-Dependientes/metabolismo , Neoplasias Hormono-Dependientes/patología , Piridinas/síntesis química , Receptores de GABA/metabolismo , Inhibidores de la Síntesis de Esteroides/síntesis química , Relación Estructura-Actividad , Neoplasias Testiculares/metabolismo , Neoplasias Testiculares/patologíaRESUMEN
Since many estrogen derivatives exhibit anti-hormone or enzyme inhibition potential, a large number of steroidal derivatives have been synthesised from appropriate precursors, in order to obtain potential therapeutics for the treatment of hormone-dependent cancers. In molecular docking studies, based on X-ray crystallographic analysis, selected D-homo and D-seco estratriene derivatives were predicted to bind strongly to estrogen receptor α (ERα), aromatase and 17,20 lyase, suggesting they could be good starting compounds for antihormonal studies. Test results in vivo suggest that these compounds do not possess estrogenic activity, while some of them showed weak anti-estrogenic properties. In vitro anti-aromatase and anti-lyase assays showed partial inhibition of these two enzymes, while some compounds activated aromatase. Aromatase activators are capable of promoting estrogen synthesis for treatment of pathological conditions caused by estrogen depletion, e.g. osteopenia or osteoporosis.
Asunto(s)
Aromatasa/metabolismo , Inhibidores Enzimáticos/farmacología , Estrenos/farmacología , Homoesteroides/farmacología , Antagonistas de Hormonas/farmacología , Secoesteroides/farmacología , Esteroide 17-alfa-Hidroxilasa/antagonistas & inhibidores , Animales , Cristalografía por Rayos X , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Estrenos/síntesis química , Estrenos/química , Estrógenos/biosíntesis , Femenino , Homoesteroides/síntesis química , Homoesteroides/química , Antagonistas de Hormonas/síntesis química , Antagonistas de Hormonas/química , Modelos Moleculares , Conformación Molecular , Ratas , Ratas Wistar , Secoesteroides/síntesis química , Secoesteroides/química , Estereoisomerismo , Esteroide 17-alfa-Hidroxilasa/metabolismo , Relación Estructura-ActividadRESUMEN
Antiprogestins with a 4' para imidazolylphenyl moiety were synthesized and their biochemical interactions with the progesterone and glucocorticoid receptor were investigated. Depending on the substitution pattern at the 17 position partial progesterone receptor (PR)-agonistic derivatives like compounds EC339 and EC336 or pure antagonists like compound EC317 were obtained. EC317 was investigated in vivo and found to be significantly more potent than RU 486 in cycling and pregnant guinea pigs. For testing the biological action progesterone receptor modulators (PRM), guinea pigs appears as a specific model when compare to pregnant human uterus. This model correlates to human conditions such as softening and widening of the cervix, the elevation of the uterine responsiveness to prostaglandins and oxytocin, and finally to induction of labor. The use of non-pregnant guinea pigs permitted the simultaneous assessment of PR-agonistic and PR-antagonistic properties and their physiological interactions with uterine and vaginal environment. These can histologically be presumed from the presence of estrogen or progesterone dominance in the genital tract tissues. The ovarian histology indicated the effects on ovulation. Corpora lutea in guinea pigs further reflects inhibitory effects of the progesterone-dependent uterine prostaglandin secretion. PRMs are initially synthesized as analogues of RU 486. They represent a heterogeneous group of compounds with different ratios of PR-agonistic and-antagonistic properties. PR-agonistic properties may be essential for uterine anti-proliferative effects. In various clinical studies these were also attributed to RU 486 or Ulipristal [1,2]. Adjusted PR-agonistic PRMs (EC312, EC313) [3] may be more effective in achieving a mitotically resting endometrium and superior uterine tumor inhibition. For the use in termination of pregnancy, progesterone-inhibitory effects are essentially needed. Even minor PR-agonistic properties compromise the therapeutic goals. Pure PR-antagonists, as EC317, clearly exceeded the gold standard RU 486 with respect to labor inducing effects. Mechanistically it is surprising that both types of compound may be potent inhibitors of ovulation.
Asunto(s)
Antagonistas de Hormonas/síntesis química , Animales , Línea Celular , Femenino , Cobayas , Antagonistas de Hormonas/química , Antagonistas de Hormonas/farmacología , Humanos , Mifepristona/química , Mifepristona/farmacología , Modelos Moleculares , Embarazo , Progesterona/antagonistas & inhibidores , Progestinas/antagonistas & inhibidores , Útero/efectos de los fármacosRESUMEN
There were synthesized new types of ribbon type steroidal dimers derived from three types of steroidal skeletons (cholic acid, etienic acid, estrone) using Cu(I) catalyzed 1, 3-dipolar cycloaddition reaction. Steroid parts of the molecular "ribbons" are linked by heterocyclic moiety, namely by 2,6-bis((1H-1,2,3-triazol-1-yl)-methyl)pyridine. Compounds synthesized possess different cytotoxic and hormone receptor modulating activities.
Asunto(s)
Androstenos/química , Ácido Cólico/química , Citotoxinas/síntesis química , Estrona/química , Antagonistas de Hormonas/síntesis química , Esteroides/síntesis química , Catálisis , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Citotoxinas/farmacología , Antagonistas de Hormonas/farmacología , Humanos , Estructura Molecular , Piridinas/química , Receptores de Esteroides/antagonistas & inhibidores , Receptores de Esteroides/metabolismo , Esteroides/farmacología , Relación Estructura-ActividadRESUMEN
A series of antiprogestins have been synthesized by partially fluorinating the steroid molecule in positions relevant for receptor binding. By introducing fluorine at the exo-methylene of the 17 spirofuran ring, we obtained partial agonists (mesoprogestins) with significant applications for antiproliferative and antiovulatory treatment strategies in gynecological therapy such as uterine fibroids, endometriosis and heavy menstrual bleeding. Compared to the standard drug RU486, our synthesized compounds exhibited considerable dissociation between antiprogestational and antiglucocorticoid PR receptors. Furthermore, our studies have shown that pure antiprogestins can be generated by partially fluorinating the 17 propenyl and propynl group or by substituting the 4' acetyl phenyl group in the 11 position using trifluromethyl group.
Asunto(s)
Halogenación/efectos de los fármacos , Antagonistas de Hormonas/síntesis química , Antagonistas de Hormonas/farmacología , Progestinas/síntesis química , Progestinas/farmacología , Animales , Femenino , Cobayas , Células HEK293 , Humanos , Espectroscopía de Resonancia Magnética , Mifepristona/análogos & derivados , Mifepristona/química , Mifepristona/farmacología , Progestinas/antagonistas & inhibidores , Receptores de Estrógenos/metabolismo , Receptores de Glucocorticoides/metabolismo , Receptores de Progesterona/antagonistas & inhibidores , Receptores de Progesterona/metabolismo , Vagina/citología , Vagina/efectos de los fármacosRESUMEN
Early studies led to the identification of 11ß-aryl-4',5'-dihydrospiro[estra-4,9-diene-17ß,4'-oxazole] analogs with potent and more selective antiprogestational activity compared to antiglucocorticoid activity than mifepristone. In the present study, we replaced the 4'-dimethylaminophenyl group of mifepristone with the benzoxazol group to give 5a-d. We also prepared the 17ß-formamido analogs 6a,b using a new synthetic strategy via the intermediate epoxide 21. These compounds were evaluated for their antagonist hormonal properties using the T47D cell-based alkaline phosphatase assay and the A549 cell-based functional assay. Compound 5c showed potent antagonist activity at GR with better selectivity for GR versus PR than mifepristone and is a promising lead for further development.
Asunto(s)
Antagonistas de Hormonas/síntesis química , Antagonistas de Hormonas/farmacología , Receptores de Glucocorticoides/antagonistas & inhibidores , Receptores de Progesterona/antagonistas & inhibidores , Esteroides/síntesis química , Esteroides/farmacología , Benzoxazoles/síntesis química , Benzoxazoles/química , Benzoxazoles/farmacología , Línea Celular Tumoral , Antagonistas de Hormonas/química , Humanos , Concentración 50 Inhibidora , Mifepristona/química , Estructura Molecular , Esteroides/química , Especificidad por Sustrato/efectos de los fármacosRESUMEN
The V1a receptor has emerged as an attractive target for a range of indications including Raynaud's disease and dysmenorrhoea. As part of an effort to discover a new class of orally active V1a antagonist, we optimised a highly lipophilic, metabolically unstable lead into a range of potent, selective and metabolically stable V1a antagonists. In this communication, we demonstrate the series-dependent effect of limiting the number of rotatable bonds in order to decrease Cytochrome P450-mediated metabolism. This effort culminated in the discovery of PF-184563, a novel, selective V1a antagonist with excellent in vitro and in vivo properties.
Asunto(s)
Antagonistas de los Receptores de Hormonas Antidiuréticas , Benzodiazepinas/síntesis química , Benzodiazepinas/farmacología , Sistema Enzimático del Citocromo P-450/metabolismo , Diseño de Fármacos , Descubrimiento de Drogas , Dismenorrea/tratamiento farmacológico , Antagonistas de Hormonas/síntesis química , Antagonistas de Hormonas/farmacología , Triazoles/síntesis química , Triazoles/farmacología , Benzodiazepinas/química , Benzodiazepinas/metabolismo , Estabilidad de Medicamentos , Femenino , Antagonistas de Hormonas/química , Antagonistas de Hormonas/metabolismo , Humanos , Microsomas/fisiología , Estructura Molecular , Triazoles/química , Triazoles/metabolismoRESUMEN
BACKGROUND: Tumor necrosis factor (TNF)-α plays a critical role in psoriasis pathogenesis, and several anti-TNF agents have been developed as therapeutic drugs in this indication. SCOPE: To present the preclinical rationale and clinical data for onercept, a novel anti-TNF agent developed for the treatment of moderate-to-severe psoriasis, and to critically evaluate the onercept clinical development program. FINDINGS: Onercept was shown in preclinical studies to inhibit TNF-α and suppress clinical signs in several inflammatory conditions. In phase II studies onercept demonstrated a therapeutic benefit in psoriasis and psoriatic arthritis and no safety issues were identified. Based on these results, a phase III program comprising three multicenter, randomized, double-blind, placebo-controlled studies examining onercept in moderate-to-severe plaque psoriasis was initiated. Following the occurrence of two cases of systemic inflammatory response syndrome (SIRS) and lower than expected efficacy results, an independent Data Safety Monitoring Board (DSMB) determined that the risk-benefit ratio was not sufficiently favorable to justify continued development, and all clinical studies were promptly terminated. Although not initially diagnosed as such by the investigators, two further SIRS events were reported, one after study discontinuation. Although an increased incidence of infection and sepsis-like events has been associated with other anti-TNF therapies, an increased risk of infection was not observed with onercept treatment. Moreover, no infectious etiology was determined in the SIRS cases. The data suggest that the SIRS reactions were due to a systemic inflammatory response. CONCLUSIONS: Despite promising early clinical results, onercept showed many of the expected risks associated with other anti-TNF agents and proved not to have an exceptional efficacy and safety profile. The clinical development of onercept highlights the critical importance of DSMBs and closely monitoring patient safety and evaluating risk-benefit profiles in large clinical programs.
Asunto(s)
Psoriasis/tratamiento farmacológico , Receptores Tipo I de Factores de Necrosis Tumoral/uso terapéutico , Receptores Señuelo del Factor de Necrosis Tumoral/uso terapéutico , Animales , Ensayos Clínicos Fase I como Asunto , Ensayos Clínicos Fase II como Asunto , Descubrimiento de Drogas , Antagonistas de Hormonas/efectos adversos , Antagonistas de Hormonas/síntesis química , Antagonistas de Hormonas/farmacología , Antagonistas de Hormonas/uso terapéutico , Humanos , Unión Proteica , Ensayos Clínicos Controlados Aleatorios como Asunto , Receptores Tipo I de Factores de Necrosis Tumoral/efectos adversos , Receptores Tipo I de Factores de Necrosis Tumoral/síntesis química , Receptores Tipo I de Factores de Necrosis Tumoral/farmacología , Síndrome de Respuesta Inflamatoria Sistémica/inducido químicamente , Síndrome de Respuesta Inflamatoria Sistémica/epidemiología , Resultado del Tratamiento , Receptores Señuelo del Factor de Necrosis Tumoral/efectos adversos , Receptores Señuelo del Factor de Necrosis Tumoral/síntesis química , Receptores Señuelo del Factor de Necrosis Tumoral/farmacología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
PURPOSE OF REVIEW: To discuss novel drug formulations being developed for the medical treatment of acromegaly and to highlight recent data from studies reporting more effective therapeutic strategies using existing drugs. RECENT FINDINGS: Despite advances in the management of acromegaly a significant number of patients remain uncontrolled. Primary medical treatment is being increasingly considered, but use of somatostatin analogues, the current mainstay of medical therapy, achieves control in only around 60% of patients, whilst 10-20% may be controlled with dopamine agonists. Consequently, improvements in drug efficacy and convenience are needed. Newer longer-acting somatostatin analogues are in development and combination regimes with the growth hormone receptor antagonist, pegvisomant, given at more cost-effective weekly doses show promising results. Somatostatin analogue-resistant tumours may respond to ligands with higher affinities to other receptors, such as pasireotide (SOM 230). Further, the combined dopamine/somatostatin receptor analogue BIM-23A760 has increased affinity to somatostatin receptors 2 and 5 and to the dopamine 2 receptor, and phase 2 clinical studies are underway. SUMMARY: These novel drugs, formulations and treatment regimes should potentially add to the armamentarium of treatment options for patients with acromegaly.
Asunto(s)
Acromegalia/tratamiento farmacológico , Química Farmacéutica/tendencias , Antagonistas de Hormonas/uso terapéutico , Somatostatina/análogos & derivados , Acromegalia/etiología , Acromegalia/metabolismo , Adenoma/complicaciones , Adenoma/tratamiento farmacológico , Adenoma/metabolismo , Relación Dosis-Respuesta a Droga , Adenoma Hipofisario Secretor de Hormona del Crecimiento/complicaciones , Adenoma Hipofisario Secretor de Hormona del Crecimiento/tratamiento farmacológico , Adenoma Hipofisario Secretor de Hormona del Crecimiento/metabolismo , Antagonistas de Hormonas/administración & dosificación , Antagonistas de Hormonas/síntesis química , Hormona de Crecimiento Humana/metabolismo , Humanos , Somatostatina/antagonistas & inhibidoresRESUMEN
Cockroach-type allatostatins (FGLamides) (ASTs) can inhibit the production of juvenile hormone in vitro, and they therefore are regarded as possible insect growth regulator (IGR) candidates for pest control. However, several shortcomings, such as the absence of in vivo effects, rapid degradation, and high production costs, preclude their practical use in pest management. To discover new IGRs, 25 novel analogues of pentapeptide (Y/FXFGLa) were designed and synthesized with different aromatic acids, fatty acids, and dicarboxylic acids as the Y/FX region replacements on the basis of previous results. Their bioactivities in vitro were determined, and the results showed that eight analogues (K14, K15, K17, K18, K19, K23, K24, and K25) were more active than the lead, core region pentapeptide. The IC(50) values of K15 and K24 (IC(50) = 1.79 and 5.32 nM, respectively) were even lower than that of the natural AST, Dippu-AST 1(IC(50) = 8 nM), which indicated both analogues have better activity than Dippu-AST 1; particularly, K15 has better activity than most natural Dippu-ASTs. A predictable and statistically meaningful hologram quantitative structure-activity relationship (HQSAR) model of 32 AST analogues (28 as training sets and 4 as test sets) was obtained. The final model suggested that a potent AST analogue should contain an aromatic group, a linker of appropriate length, and the FGLa portion. These results will be useful in the design of new AST analogues that are structurally related to the training set compounds.
Asunto(s)
Antagonistas de Hormonas/química , Antagonistas de Hormonas/farmacología , Neuropéptidos/química , Neuropéptidos/farmacología , Animales , Cucarachas , Femenino , Antagonistas de Hormonas/síntesis química , Modelos Moleculares , Neuropéptidos/síntesis química , Relación Estructura-Actividad CuantitativaRESUMEN
A series of mifepristone derivatives with different "linker groups" in position 4' of the phenyl ring in the 11beta-position of the steroid scaffold (2-41) have been synthesized. Their antigestagenic activites were determined in a cell-based assay (alkali phosphatase assay in T47-D breast cancer cells) and compared with that of the parent compound mifepristone. SAR and QSAR studies reveal the influence of both lipophilicity and partial charge based van der Waals surface area descriptors on biological activity. Within the series of compounds described in this study, three mifepristone derivatives are identified with considerably high antigestagenic activity. These compounds are regarded as useful starting materials for the synthesis of either physiologically stable or cleavable progesterone receptor-binding conjugates for therapeutic or diagnostic purposes.
Asunto(s)
Antagonistas de Hormonas/síntesis química , Mifepristona/análogos & derivados , Mifepristona/síntesis química , Fosfatasa Alcalina/metabolismo , Neoplasias de la Mama , Línea Celular Tumoral , Femenino , Antagonistas de Hormonas/farmacología , Humanos , Mifepristona/farmacología , Modelos Moleculares , Neoplasias Hormono-Dependientes , Receptores de Progesterona/metabolismo , Análisis de Regresión , Relación Estructura-ActividadRESUMEN
2-Trifluoromethyl-4-aminobenzimidazoles were previously identified by screening to be active antagonists of the gonadotropin releasing hormone receptor (GnRH-R). Structure activity relationships and diversity oriented synthesis are shown here in greater detail. 2-Substituted benzimidazoles were synthesized in parallel by the coupling of carboxylic acids with a latent intermediate diamine monomer to yield the desired benzimidazoles in fair yields. A catch and release strategy was employed as a product isolation technique, followed by RP-HPLC to obtain products of desired purity for biological evaluation. Two libraries were prepared and screened to determine the optimal substitution for inhibitory activity against GnRH-R. The initial library focused on substituted phenyl, pyridine, and thiophenes. The follow-up library focused on substitution patterns observed in the initial library members and generated compounds with IC(50) values lower than 100 nM at the GnRH-R.
Asunto(s)
Bencimidazoles/síntesis química , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Antagonistas de Hormonas/síntesis química , Bencimidazoles/farmacología , Ácidos Carboxílicos/química , Técnicas Químicas Combinatorias , Diaminas/química , Antagonistas de Hormonas/farmacología , Concentración 50 Inhibidora , Bibliotecas de Moléculas Pequeñas/síntesis química , Relación Estructura-ActividadRESUMEN
The glycoprotein hormones, luteinizing hormone, follicle-stimulating hormone and thyroid stimulating hormone, are important regulators of reproductive and metabolic processes. However, because of the nature of their ligand-receptor interactions that contain multiple contact sites, classical small molecule drug discovery strategies have not been successful. However, recent advances in screening and combinatorial chemistry strategies have identified chemical series that act allosterically as positive, negative or mixed modulators of the glycoprotein hormone receptors. This review will discuss the discovery and highlight the currently known series of allosteric modulators to this therapeutically important family of G-protein coupled receptors. Lastly, we will present potential mechanisms whereby the different series could modulate receptor function in the context of currently held theory and known structure of G protein-coupled receptors.
Asunto(s)
Diseño de Fármacos , Glicoproteínas/metabolismo , Antagonistas de Hormonas/uso terapéutico , Hormonas/uso terapéutico , Receptores de Péptidos/metabolismo , Regulación Alostérica/efectos de los fármacos , Regulación Alostérica/fisiología , Animales , Reguladores de Proteínas de Unión al GTP/síntesis química , Reguladores de Proteínas de Unión al GTP/uso terapéutico , Antagonistas de Hormonas/síntesis química , Hormonas/síntesis química , Humanos , Modelos Biológicos , Receptores de Péptidos/agonistas , Receptores de Péptidos/antagonistas & inhibidores , Bibliotecas de Moléculas Pequeñas/análisis , Bibliotecas de Moléculas Pequeñas/uso terapéuticoRESUMEN
Substitution of the C-11 aniline of mifepristone can provide compounds with altered pharmacokinetic and pharmacodynamic (PK/PD) profiles that may find use for new indications. The development of new steroid intermediates and specialized library synthesis methods were required to enable the efficient preparation of structurally complex C-11 modified mifepristone analogs.
Asunto(s)
Química Farmacéutica/métodos , Mifepristona/análogos & derivados , Mifepristona/síntesis química , Biblioteca de Péptidos , Compuestos de Anilina/química , Antagonistas de Hormonas/síntesis química , Mifepristona/química , Modelos BiológicosRESUMEN
A novel series of oxa-steroids 6 derived from (8S, 13S, 14R)-7-oxa-estra-4,9-diene-3,17-dione 1 have been synthesized and identified as potent and selective progesterone receptor antagonists. These novel oxa-steroids showed similar potency to mifepristone. Preliminary SAR study resulted in the most potent 17-phenylethynyl oxa-steroid 6i wih an IC(50) of 1.4nM. In contrast to the equipotent mifepristone toward the progesterone receptor (PR) and glucocorticoid receptor (GR), compound 6i had over 200-fold selectivity for PR over GR.
Asunto(s)
Receptores de Progesterona/antagonistas & inhibidores , Esteroides/síntesis química , Esteroides/farmacología , Fosfatasa Alcalina/biosíntesis , Neoplasias de la Mama/enzimología , Línea Celular Tumoral , Inducción Enzimática/efectos de los fármacos , Femenino , Genes Reporteros/efectos de los fármacos , Antagonistas de Hormonas/síntesis química , Antagonistas de Hormonas/farmacología , Humanos , Mifepristona/síntesis química , Mifepristona/farmacología , Receptores de Glucocorticoides/efectos de los fármacos , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
Aedes aegypti PISCF-allatostatin or allatostatin-C (Ae-AS-C) was isolated using a combination of high performance liquid chromatography and enzyme-linked immunosorbent assay (ELISA). The matrix-assisted laser desorption/ionization time-of-flight (TOF) mass spectrum of positive ELISA fractions revealed a molecular mass of 1919.0 Da, in agreement with the sequence qIRYRQCYFNPISCF, with bridged cysteines. This sequence was confirmed by matrix-assisted laser desorption/ionization tandem TOF/TOF mass spectrometry analysis. The corresponding Ae-AS-C cDNA was amplified by PCR, and the sequence of the peptide was confirmed. An in vitro radiochemical assay was used to study the inhibitory effect of synthetic Ae-AS-C on juvenile hormone biosynthesis by the isolated corpora allata (CA) of adult female A. aegypti. The inhibitory action of synthetic Ae-AS-C was dose-dependent; with a maximum at 10(-9) m. Ae-AS-C showed no inhibitory activity in the presence of farnesoic acid, an immediate precursor of juvenile hormone, indicating that the Ae-AS-C target is located before the formation of farnesoic acid in the pathway. The sensitivity of the CA to inhibition by Ae-AS-C in the in vitro assay varied during the adult life; the CA was most sensitive during periods of low synthetic activity. In addition, the levels of Ae-AS-C in the brain were studied using ELISA and reached a maximum at 3 days after eclosion. These studies suggest that Ae-AS-C is an important regulator of CA activity in A. aegypti.
Asunto(s)
Aedes/metabolismo , Corpora Allata/efectos de los fármacos , Antagonistas de Hormonas/farmacología , Hormonas de Insectos/biosíntesis , Hormonas Juveniles/biosíntesis , Neuropéptidos/farmacología , Aedes/efectos de los fármacos , Aedes/crecimiento & desarrollo , Secuencia de Aminoácidos , Animales , Cromatografía Líquida de Alta Presión , Clonación Molecular , Corpora Allata/metabolismo , Ensayo de Inmunoadsorción Enzimática , Femenino , Antagonistas de Hormonas/síntesis química , Antagonistas de Hormonas/química , Hormonas de Insectos/genética , Hormonas Juveniles/genética , Datos de Secuencia Molecular , Neuropéptidos/síntesis química , Neuropéptidos/química , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/metabolismo , Reacción en Cadena de la Polimerasa , Conejos , Homología de Secuencia de Aminoácido , Espectrometría de Masa por Láser de Matriz Asistida de Ionización DesorciónRESUMEN
The human progesterone receptor (PR) binding affinity and the PR agonistic or antagonistic potency of tetrahydronaphthofuranone derivatives were shown previously to be markedly influenced by substituents at the 6- and 7-positions. Here, we synthesized tetrahydrobenzindolones possessing a lactam ring, which enabled us to modify the 6- and 7-positions more freely, since tetrahydrobenzindolones are chemically more stable than tetrahydronaphthofuranones. The tetrahydrobenzindolone derivatives generally showed higher PR binding affinity than the corresponding tetrahydronaphthofuranones. We also succeeded in separating the agonistic and antagonistic activities by choosing suitable substituent groups at the 6- and/or 7-position(s) of the tetrahydrobenzindolone. The effects of representative agonists, 12c (CP8668), and 14a (CP8816), and a representative antagonist, 15f (CP8661), were confirmed in in vivo tests. In this report, we mainly describe the synthesis and structure-activity relationships (SAR) of tetrahydrobenzindolone derivatives, as new nonsteroidal PR ligands.
Asunto(s)
Indoles/síntesis química , Indoles/farmacología , Receptores de Progesterona/metabolismo , Línea Celular , Evaluación Preclínica de Medicamentos , Furanos/química , Furanos/farmacología , Antagonistas de Hormonas/síntesis química , Antagonistas de Hormonas/química , Antagonistas de Hormonas/farmacología , Humanos , Técnicas In Vitro , Indoles/química , Cinética , Ligandos , Naftoles/química , Naftoles/farmacología , Receptores de Progesterona/agonistas , Receptores de Progesterona/antagonistas & inhibidores , Sesquiterpenos/química , Sesquiterpenos/farmacología , Relación Estructura-Actividad , Tetrahidronaftalenos/química , Tetrahidronaftalenos/farmacologíaRESUMEN
We have synthesized a series of nonsteroidal progesterone receptor (PR) ligands, tetrahydronaphthofuranones, structurally based on the fungal metabolite PF1092C. Structure-activity relationship studies revealed that substituents at the 6- and 7-positions were critical for PR binding affinity and for agonist or antagonist activity. Compounds in this series, exemplified by 19i, exhibited high affinity and high specificity for PR over other steroid hormone receptors and acted as selective PR antagonists. Further modification of PF1092C may generate compounds of potential pharmacological interest.
Asunto(s)
Furanos/síntesis química , Furanos/farmacología , Receptores de Progesterona/metabolismo , Tetrahidronaftalenos/síntesis química , Tetrahidronaftalenos/farmacología , Línea Celular , Furanos/química , Antagonistas de Hormonas/síntesis química , Antagonistas de Hormonas/química , Antagonistas de Hormonas/farmacología , Humanos , Técnicas In Vitro , Cinética , Ligandos , Naftoles/síntesis química , Naftoles/química , Naftoles/farmacología , Receptores de Progesterona/agonistas , Receptores de Progesterona/antagonistas & inhibidores , Sesquiterpenos/síntesis química , Sesquiterpenos/química , Sesquiterpenos/farmacología , Relación Estructura-Actividad , Tetrahidronaftalenos/químicaRESUMEN
Eleven new analogues were synthesized by modification of the potent oxytocin antagonist (OTA) [(S)Pmp(1), D-Trp(2), Pen(6), Arg(8)]-Oxytocin, or PA (parent antagonist), in which (S)Pmp = beta,beta-(3-thiapentamethylene)-beta-mercapto-propionic acid. By internal acylation of Lys, Orn, L-1,4-diaminobutyric acid (Dab), L-1,3-diaminopropionic acid (Dap) at position 4 with the C-terminal Gly of the peptide tail, we prepared cyclo-(4-9)-[Lys(4), Gly(9)]-PA (pA(2) = 8.77 +/- 0.27), 1, and cyclo-(4-9)-[Orn(4), Gly(9)]-PA (pA(2) = 8.81 +/- 0.25), 3, which are equipotent with PA (pA(2) = 8.68 +/- 0.18) in the rat uterotonic assay and cyclo-(4-9)-[Dab(4), Gly(9)]-PA, 4, cyclo-(4-9)-[Dap(4), Gly(9)]-PA, 5, and cyclo-(4-9)-[Pmp(1), Lys(4), Gly(9)]-PA, 2, which were weaker OTAs. Neither 1 nor 3 had activity as agonists or antagonists in the antidiuretic assay. In the pressor assay, both analogues 1 and 3, with pA(2) = 7.05 +/- 0.10 and pA(2) = 6.77 +/- 0.12, respectively, are somewhat weaker antagonists than PA (pA(2) = 7.47 +/- 0.35) showing significant gain in specificity. The [desamido(9)] PA-ethylenediamine monoamide, 6, and the dimer ([desamido(9)]-PA)(2) ethylenediamine diamide, 7, had lower potency in the uterotonic assay than PA. Additionally, we synthesized cyclo-(1-5)-[(HN)Pmp(1), Asp(5)]-PA, 8, inactive in all tests, which suggests that the intact Asn(5) side chain may be critical in the interaction of the OTAs with the oxytocin (OT) receptor. Similarly, cyclo-(5-9)-[Dap(5), Gly(9)]-PA, 9, had very low uterotonic potency. Two derivatives of PA truncated from the C-terminus were internally cyclized to Lys(4), giving rise to cyclo-(4-8)-desGly-NH(2)(9)[Lys(4), Arg(8)]-PA, 10 (pA(2) = 8.35 +/- 0.20), which maintains the high potency of PA and has no activity in the rat antidiuretic assay, and in the rat pressor assay it is about ten times weaker (pA2 = 6.41 +/- 0.15) than PA (pA2 = 7.47 +/- 0.35), thus showing gains in specificity, and to cyclo-(4-7)-desArg-Gly-(NH)(2)(8-9)[Lys(4), Pro(7))-PA, 11, which has much weaker potency than PA. Synthesis of cyclo-(4-6)-desPro-Arg-Gly-(NH)(2)(7-9)[Lys(4)]-PA failed.